about
Towards effective and efficient patient-specific quality assurance for spot scanning proton therapySpot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes.Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial.Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practiceClinical implementation of intensity modulated proton therapy for thoracic malignancies.Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05)Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients.External-beam accelerated partial breast irradiation using multiple proton beam configurations.Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment.Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLCDetermination of elemental tissue composition following proton treatment using positron emission tomographyTherapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation.Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.Feasibility of proton-activated implantable markers for proton range verification using PET.Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticlesHuman papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells.Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting.Motion-robust intensity-modulated proton therapy for distal esophageal cancer.
P50
Q26852392-2863A5FB-F7F2-445C-B0DC-DE8B2DB76916Q33275400-1BA8E2E4-0DB1-4C6C-9DEC-71E6C6913CBBQ33645532-A8304320-7E8C-4668-B1F5-E02A65D196AFQ33864141-D394E0B0-6026-44A7-8737-729835830E84Q34228231-11AB8BCD-2F99-4135-8AB7-1FC26D4EA88EQ34615702-D8C92423-FF0A-4B64-A33F-EFAF06ED058EQ35050966-7537FA7F-CA27-43EA-810D-3EE35BC29033Q35095184-77FD4C1F-329D-45B5-BA80-CFA7DEE3F100Q35216097-F67EC223-0C5E-484D-AE81-519C75B7C18BQ35449770-EFD8F122-44D7-4634-8420-30A764CA7662Q35644734-FAC8B750-D7EC-44C0-9D11-400C579AEC9CQ35933778-A8A2C7EF-B978-4A23-BFE8-2D7585B191F8Q36729045-3D3F9F06-DF8B-47D0-BF22-6029EDCA883EQ36866800-7BD3C9D0-68A6-46B3-894E-3AE52D8C3141Q37148972-4C785633-2575-4C26-BBAA-9446799BF13CQ37440963-EA7CA1BE-50D4-4F79-84B8-00AB27463D75Q37587783-179EE751-D9FE-4E13-9865-1703E7B127E9Q37720661-93A1E226-D951-4BBE-AD06-73E9E449D6CFQ38366112-161D1A87-C9B8-4423-ADC8-0DB69D5123A1Q38723433-776CF7B2-4487-4911-A642-F1B059FD19DFQ38990272-96915767-FE30-4F49-9BAF-6808A1F77634Q39692840-B2973D99-6573-4644-A803-9993D839CB6BQ39952215-4EB3AF44-7EE7-4EEE-97F1-058872346C44
P50
description
onderzoeker
@nl
name
Michael Gillin
@ast
Michael Gillin
@en
Michael Gillin
@es
Michael Gillin
@sl
type
label
Michael Gillin
@ast
Michael Gillin
@en
Michael Gillin
@es
Michael Gillin
@sl
prefLabel
Michael Gillin
@ast
Michael Gillin
@en
Michael Gillin
@es
Michael Gillin
@sl